Christopher Kaiser
Neurology · Fort Myers, FLNPI 1730705021
Payments from drug & device makers
Across 699 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novartis$998
- AbbVie$928
- UCB, Inc.$836
- Amgen$766
- Lundbeck LLC$731
- plus $9K from 54 others
What the payments were for
- Food & beverage$14,39299%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,489 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 42 | $330,119 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $224,654 |
| NuplazidPimavanserin Tartrate | 30 | $144,685 |
| Nurtec OdtRimegepant Sulfate | 74 | $125,518 |
| GocovriAmantadine Hcl | 28 | $118,380 |
| AustedoDeutetrabenazine | 13 | $99,055 |
| UbrelvyUbrogepant | 53 | $71,952 |
| RytaryCarbidopa/Levodopa | 31 | $63,198 |
| QuliptaAtogepant | 52 | $62,288 |
| Aimovig AutoinjectorErenumab-Aooe | 43 | $32,590 |
| AptiomEslicarbazepine Acetate | 16 | $29,891 |
| BriviactBrivaracetam | 17 | $26,566 |
| Emgality PenGalcanezumab-Gnlm | 36 | $25,746 |
| Ajovy SyringeFremanezumab-Vfrm | 15 | $16,985 |
| Droxidopa | 29 | $14,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $107 | $224,65424 claims |
| Acadia Pharmaceuticals IncNuplazid | $292 | $144,68530 claims |
| AbbVieUbrelvy, Qulipta | $928 | $134,240105 claims |
| PfizerNurtec Odt | $347 | $125,51874 claims |
| MDD US Operations, LLCGocovri | $156 | $118,38028 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $278 | $99,05513 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $136 | $65,49156 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $95 | $29,89116 claims |
| UCB, Inc.Briviact | $836 | $26,56617 claims |
| Eisai Inc.Fycompa | $274 | $13,88511 claims |
| AstraZenecaBrilinta | $1,178 | $8,78014 claims |
| Upsher-smith Laboratories LLCTopiramate | $127 | $1,895158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.
Other neurology in Fort Myers
- Wendy BondFort Myers$14.7M
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.